(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -21.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.73%.
Spero Therapeutics's revenue in 2026 is $61,186,000.On average, 3 Wall Street analysts forecast SPRO's revenue for 2026 to be $47,247,618, with the lowest SPRO revenue forecast at $45,394,771, and the highest SPRO revenue forecast at $48,637,254. On average, 3 Wall Street analysts forecast SPRO's revenue for 2027 to be $188,990,473, with the lowest SPRO revenue forecast at $181,579,082, and the highest SPRO revenue forecast at $194,549,016.
In 2028, SPRO is forecast to generate $1,954,870,207 in revenue, with the lowest revenue forecast at $1,878,208,630 and the highest revenue forecast at $2,012,366,389.